Skip to main content

Table 2 Medication taken at enrollment

From: Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort

Medication

Number (%)

Mean dose (SD)

Dose range

Prednisolone

1430 (77.46 %)

11.08 mg (12.78)

0.50–200 mg

Antimalarial

1333 (72.21 %)

291.19 mg (104.56)a

28.57–600 mga

Methotrexate

75 (4.06 %)

13.79 mg (6.73)

2.50–50 mg

Azathioprine

412 (22.32 %)

73.99 mg (30.29)

12.50–200 mg

Mycophenolate mofetil

306 (16.58 %)

1247.70 mg (546.96)

50–3000 mg

Mycophenolic acid

41 (2.22 %)

1102.93 mg (645.86)

180–2160 mg

Leflunomide

38 (2.06 %)

15.53 mg (5.49)

10–30 mg

Cyclosporine

35 (1.90 %)

126.43 mg (65.29)

50–300 mg

Cyclophosphomideb

73 (3.95 %)

N/A

N/A

Rituximabb

13 (0.70 %)

N/A

N/A

Belimumabb

15 (0.81 %)

N/A

N/A

Any Immunosuppressantc

940 (50.92 %)

N/A

N/A

  1. aBased on hydroxychloroquine dosing - Indonesia and Thailand predominantly use chloroquine. bTaken in the last 6 months. cEither methotrexate, azathioprine, mycophenolate, leflunomide, cyclosporine, cyclophosphamide, rituximab and/or belimumab. Maximum recommended dose: hydroxychloroquine ≤400 mg; methotrexate ≤30 mg; azathioprine ≤200 mg; mycophenolate mofetil ≤3000 mg; mycophenolic acid ≤2160 mg; leflunomide ≤20 mg
  2. N/A - dosing not applicable